TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29760009

Group type: EXPERIMENTAL
Intervention: Theory-based behavioural intervention to reduce formula milk intake
Number of subjects: 669

Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 669
Study: 26812574

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Brain Health Workshop (BHW) (Control)
Number of subjects: 70
Study: 24865129

Group type: EXPERIMENTAL
Intervention: Bifluorid 12 two applications/year
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Duraphat two applications/year
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Bifluorid 12 four applications/year
Number of subjects: 1365

Group type: COMPARATOR
Intervention: No fluoride varnish at school (Control)
Number of subjects: 1365
Study: 22665144

Group type: EXPERIMENTAL
Intervention: Isolated soy isoflavone supplementation (25 g of isoflavone-rich soy protein daily)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Milk protein-matched placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Isolated soy isoflavone supplementation
Number of subjects: 313
Study: 20438830

Group type: EXPERIMENTAL
Intervention: Diclofenac exposure
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (non-teratogenic agents)
Number of subjects: 145
Study: 17627707

Group type: EXPERIMENTAL
Intervention: Indoprocaf
Number of subjects: 297

Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 297
Study: 15735614

Group type: EXPERIMENTAL
Intervention: BIBN4096BS (2.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12853500

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg bid)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA), 400 microg bid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Salmeterol or Placebo after the run-in
Number of subjects: 45
Study: 10912141

Group type: EXPERIMENTAL
Intervention: Guideline-oriented care (B2)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Routine care (A1, B1)
Number of subjects: 1010
Study: 8643858

Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg/day) starting from the 6th irradiation session throughout the treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (baseline treatment only, fluconazole given only when mycotic infections appeared)
Number of subjects: 80
Study: 1353996

Group type: EXPERIMENTAL
Intervention: Cetirizine (CTZ) 10 mg single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine (TER) 60 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine (CTZ) 10 mg once a day for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine (TER) 60 mg b.i.d. for 3 weeks
Number of subjects: 0
Study: 6407047

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate (0.1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 or 0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (double-blind)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate (0.1 mg) without reversal injection
Number of subjects: 0
Study: 31254340

Group type: EXPERIMENTAL
Intervention: Practitioner-facilitated personalized nutrition intervention (n=36)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard nutrition-based gene test report (control; n=19)
Number of subjects: 55
Study: 28957983

Group type: EXPERIMENTAL
Intervention: Group therapy intervention (modified constraint-induced movement therapy) for 3 hours for 10 consecutive days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Individual modified constraint-induced movement therapy for 3 hours for 10 consecutive days
Number of subjects: 36
Study: 27156611

Group type: EXPERIMENTAL
Intervention: RHZEL (RHZE + levofloxacin)
Number of subjects: 57

Group type: COMPARATOR
Intervention: RHZE (rifampicin, isoniazid, pyrazinamide and ethambutol)
Number of subjects: 57
Study: 25099160

Group type: EXPERIMENTAL
Intervention: Work Productivity Survey (WPS)
Number of subjects: 0
Study: 23031428

Group type: EXPERIMENTAL
Intervention: Four-layer bandage (4LB)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Short-stretch bandage (SSB)
Number of subjects: 424
Study: 20590736

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 319

Group type: COMPARATOR
Intervention: Voglibose 0.2 mg thrice daily
Number of subjects: 319
Study: 18001608

Group type: EXPERIMENTAL
Intervention: Over-the-counter and prescription medications (oral, topical, or injectable routes)
Number of subjects: 0
Study: 16270633

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.0 mg/kg b.i.d on two days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0, 0.01, 1 microM) in cultured human umbilical endothelial cells
Number of subjects: 9
Study: 14589465

Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal anuloplasty (IDETA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 53
Study: 10635302

Group type: EXPERIMENTAL
Intervention: Group A (UFT 300‐450 mg/day, 5 days a week and 5‐FU 440‐600 mg/m2/24 hr once a week)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Group B (UFT less than 300 mg/day, 5 days a week, and/or 5‐FU less than 440 mg/m2/24 hr once a week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group C (non‐PMC cases matched for other background factors)
Number of subjects: 22
Study: 7772361

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg intravenous (i.v.) ondansetron
Number of subjects: 57

Group type: COMPARATOR
Intervention: 0.075 mg/kg i.v. droperidol
Number of subjects: 57
Study: 2373131

Group type: EXPERIMENTAL
Intervention: Metoprolol CR 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol CR 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7380750

Group type: EXPERIMENTAL
Intervention: 12-session interpersonal skills training program including instruction in Introduction and Small Talk, Asking for Help, Differing with Others, and Handling Criticism.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 12-session interpersonal skills training program
Number of subjects: 16
Study: 30762400

Group type: EXPERIMENTAL
Intervention: Biobehavioral intervention (BBI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 160
Study: 29374961

Group type: EXPERIMENTAL
Intervention: Mobile application lifestyle modification (app user group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual practice lifestyle modification (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (app user and control)
Number of subjects: 47
Study: 27529274

Group type: EXPERIMENTAL
Intervention: Enriched-β-Conglycinin Soybean (Nanahomare)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Low-β-Conglycinin Soybean (Placebo)
Number of subjects: 134
Study: 24766179

Group type: EXPERIMENTAL
Intervention: Group diabetes education led by health promoters (4 monthly sessions)
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1570
Study: 22673961

Group type: EXPERIMENTAL
Intervention: HeartCode™ Basic Life Support (BLS)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Instructor-led (IL) course
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Monthly practice of CPR skills
Number of subjects: 606

Group type: COMPARATOR
Intervention: No further practice
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Initial course type (HeartCode™ BLS vs IL)
Number of subjects: 606
Study: 19193417

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 10 mg alfuzosin daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 102
Study: 17261462

Group type: EXPERIMENTAL
Intervention: More intensive educational/behavioral/pharmacologic intervention
Number of subjects: 309

Group type: COMPARATOR
Intervention: Less intensive information and referral intervention
Number of subjects: 309
Study: 15068150

Group type: EXPERIMENTAL
Intervention: Checker game moves (1 to 4 steps)
Number of subjects: 28
Study: 11676358

Group type: EXPERIMENTAL
Intervention: Daytime diuretic therapy (azosemide 60 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Minor tranquilizer
Number of subjects: 51
Study: 9559686

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Salvage operations (radiotherapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Salvage operations (chemoradiotherapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Planned neck dissections (radiotherapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Planned neck dissections (chemoradiotherapy)
Number of subjects: 100
Study: 8178408

Group type: EXPERIMENTAL
Intervention: KLH (1 mg intracutaneously, followed by 30 mg weekly for 6 weeks and then monthly for 1 year)
Number of subjects: 161

Group type: COMPARATOR
Intervention: etoglucid (0.565 g weekly for 6 weeks and then monthly for 1 year)
Number of subjects: 161
Study: 2959425

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: diltiazem
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 50
Study: 30466622

Group type: EXPERIMENTAL
Intervention: A. annua tea infusion (1l/d of dry leaf/twig tea infusions divided into 3 aliquots daily for 7 days)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: A. afra tea infusion (1l/d of dry leaf/twig tea infusions divided into 3 aliquots daily for 7 days)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Praziquantel (PZQ) treatment (followed manufacturer posology)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: All treatment arms (A. annua, A. afra, PZQ)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: PZQ and A. afra treatment
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: PZQ and A. annua treatment
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: A. afra treatment in males
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: PZQ and A. afra treatment in females
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: A. annua treatment
Number of subjects: 800
Study: 27858689

Group type: EXPERIMENTAL
Intervention: TENS+Exercise
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: KT+Exercise
Number of subjects: 69

Group type: COMPARATOR
Intervention: Exercise (Control)
Number of subjects: 69
Study: 26424105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414

Group type: COMPARATOR
Intervention: Usual care plus the HFM website
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Adjusted care pathway with an interactive platform (e-Vita platform)
Number of subjects: 414
Study: 23036856

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (360 minutes/week)
Number of subjects: 202
Study: 22037175

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pulsed magnetic field (PMF)
Number of subjects: 38
Study: 18299094

Group type: EXPERIMENTAL
Intervention: Interscalene block with catheter installation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular local anesthetic with catheter installation
Number of subjects: 60
Study: 12593999

Group type: EXPERIMENTAL
Intervention: Combined rosiglitazone and clomiphene citrate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clomiphene citrate monotherapy
Number of subjects: 50
Study: 10330960

Group type: EXPERIMENTAL
Intervention: Antilymphocyte antibody induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induction therapy with cyclosporine, azathioprine, and prednisone
Number of subjects: 0
Study: 8675969

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2205078

Group type: EXPERIMENTAL
Intervention: tranexamic acid treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study: 75438

Group type: EXPERIMENTAL
Intervention: Egg and cows' milk exclusion diet (soya-based milk substitute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet (egg and cows' milk preparation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: First diet period (egg and cows' milk exclusion diet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trial diet (egg and cows' milk exclusion diet)
Number of subjects: 20
Study: 30710602

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard surgical excision
Number of subjects: 256
Study: 28942094

Group type: EXPERIMENTAL
Intervention: MAT9001 (4 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPA-EE (4 g/d)
Number of subjects: 0
Study: 25043197

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 120 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 180 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) 240 μg
Number of subjects: 0
Study: 23402711

Group type: EXPERIMENTAL
Intervention: Food Exposure (FE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror Exposure (ME)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 0
Study: 21439168

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 micrograms, once daily for 15 days
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 19524176

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/day (17 patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg/day (16 patients)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hypertensive group pre-treatment
Number of subjects: 33
Study: 17925066

Group type: EXPERIMENTAL
Intervention: Short-acting β2-agonist (albuterol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting β2-agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 14984807

Group type: EXPERIMENTAL
Intervention: Goûter (snack) eaters (GE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-goûter snack eaters (NGSE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Goûter eaters (GE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-goûter non-snack eaters (NGNSE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blood variables
Number of subjects: 24
Study: 11521801

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9564130

Group type: EXPERIMENTAL
Intervention: Achievement Orientation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (Age-matched controls)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 7801759

Group type: COMPARATOR
Intervention: Chevron osteotomy alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chevron osteotomy with adductor tenotomy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 3132428

Group type: EXPERIMENTAL
Intervention: sustained-release buccal nitroglycerin (2.5 mg, given 8-hourly)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 30902115

Group type: EXPERIMENTAL
Intervention: GHQ-28
Number of subjects: 322
Study: 29051184

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (20 ± 2.5 mg/kg per day for 12 months)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 207
Study: 26475802

Group type: EXPERIMENTAL
Intervention: Crystalloid (Ringers‐acetate 20 ml kg(‐1), n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colloid (Venofundin 10 ml kg(‐1), n=15)
Number of subjects: 30
Study: 23972196

Group type: EXPERIMENTAL
Intervention: Educational intervention on GPs' PIPs for older patients (conducted from January 2006 to June 2006)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Another educational intervention (control group)
Number of subjects: 449
Study: 21445604

Group type: EXPERIMENTAL
Intervention: Cold therapy (COLD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 19023851

Group type: EXPERIMENTAL
Intervention: Vimala massage plus usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 17192501

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet containing 15 mg of pioglitazone plus 850 mg metformin (fed state)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fixed-dose combination tablet containing 15 mg of pioglitazone plus 850 mg metformin (fasted state)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet (fed state)
Number of subjects: 28
Study: 15519010

Group type: EXPERIMENTAL
Intervention: Distal protection using the GuardWire balloon occlusion device
Number of subjects: 801

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 801
Study: 11314807

Group type: EXPERIMENTAL
Intervention: Quick Check software algorithm for CD follow-up
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 105
Study: 9727512

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of dorzolamide and latanoprost
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7804386

Group type: EXPERIMENTAL
Intervention: Bupropion (225-450 mg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nortriptyline (75-150 mg/day)
Number of subjects: 115
Study: 3164781

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 191
Study: 31799628

Group type: EXPERIMENTAL
Intervention: My Retainers mobile application
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no electronic reminders)
Number of subjects: 84
Study: 29567664

Group type: EXPERIMENTAL
Intervention: Congenital Heart Assessment Tool (CHAT)
Number of subjects: 12
Study: 28552240

Group type: EXPERIMENTAL
Intervention: Manual heating of the radial artery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subcutaneous nitroglycerin plus diltiazem (drug treatment group)
Number of subjects: 90
Study: 25078718

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation of the occipital nerves
Number of subjects: 157
Study: 24047763

Group type: COMPARATOR
Intervention: HUU (HIV-uninfected infants born to HIV-uninfected mothers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-4a (immediate-ART, interrupted at 1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-3 (deferred-ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-4b (immediate-ART, interrupted at 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEU (HIV-exposed uninfected)
Number of subjects: 0
Study: 21962292

Group type: EXPERIMENTAL
Intervention: IPTp and ITNs combined
Number of subjects: 5775

Group type: EXPERIMENTAL
Intervention: IPTp alone
Number of subjects: 5775

Group type: EXPERIMENTAL
Intervention: ITNs alone
Number of subjects: 5775

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 5775
Study: 18226672

Group type: EXPERIMENTAL
Intervention: EAMD+OC (triphasic OC containing 180‐250 mcg norgestimate/25 mcg ethinyl estradiol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: EAMD controls
Number of subjects: 6
Study: 16741261

Group type: EXPERIMENTAL
Intervention: 15 degrees head-down tilt (HDT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Upright seated (URS) posture
Number of subjects: 7
Study: 14993084

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.3 mg/kg, maximum 15 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study: 10940061

Group type: EXPERIMENTAL
Intervention: Polyglactin 910 (absorbable suture)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nylon (nonabsorbable suture)
Number of subjects: 10
Study: 9324339

Group type: EXPERIMENTAL
Intervention: Regimen A (cyclophosphamide, high-dose methotrexate, vincristine, prednisone, intrathecal chemoprophylaxis)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Regimen B (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, cytarabine, coordinated intrathecal chemotherapy)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 134

Group type: COMPARATOR
Intervention: Regimen B
Number of subjects: 134
Study: 8404942

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 3027601

Group type: EXPERIMENTAL
Intervention: Sodium valproate (20 mg X 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg X 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29433485

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma with wrist splints
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wrist splint (control)
Number of subjects: 41
Study: 27872032

Group type: EXPERIMENTAL
Intervention: Empowering advertisements
Number of subjects: 710106

Group type: COMPARATOR
Intervention: Nonempowering advertisements
Number of subjects: 710106

Group type: EXPERIMENTAL
Intervention: Advertisements containing empowering content
Number of subjects: 710106

Group type: EXPERIMENTAL
Intervention: Advertisements emphasizing health effects of smoking
Number of subjects: 710106

Group type: EXPERIMENTAL
Intervention: Advertisements appearing at the top right of the page
Number of subjects: 710106

Group type: EXPERIMENTAL
Intervention: Advertisements appearing at the bottom of a list
Number of subjects: 710106